Salarius Pharmaceuticals Stock Trading Halted Pending News
ByAinvest
Saturday, Aug 16, 2025 9:54 am ET1min read
SLRX--
In the recent past, Salarius Pharmaceuticals has been actively working on its reverse stock split, which was announced on August 14, 2025. The company aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement by reducing its outstanding shares from approximately 7.6 million to 509,000 shares. This move is expected to take effect on August 18, 2025 [1].
Additionally, Salarius Pharmaceuticals has been making significant strides in its oncology drug development. The company has reported promising clinical trial results for its LSD1 inhibitor seclidemstat (SP-2577), which is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [2]. The drug has shown supporting evidence in inhibiting LSD1, a validated target in cancer treatment.
Furthermore, Salarius Pharmaceuticals has announced a merger with Decoy Therapeutics, a private preclinical biopharmaceutical company. The merger, announced on January 13, 2025, aims to form a new entity focused on developing peptide conjugate therapeutics for respiratory viruses and cancer. The combined company will leverage Decoy's IMP3ACT™ platform for rapid drug design [3].
The pending news is likely related to these ongoing developments or other significant announcements that Salarius Pharmaceuticals may have in store. Investors are advised to monitor the situation closely and stay updated on any official communications from the company.
References:
[1] https://www.stocktitan.net/news/SLRX/
[2] https://www.stocktitan.net/news/SLRX/
[3] https://www.stocktitan.net/news/SLRX/
Salarius Pharmaceuticals (SLRX) trading has been halted due to pending news. No further information is available at this time.
Salarius Pharmaceuticals (SLRX) has seen its trading halted due to pending news, with no further information available at this time. The stock has been under scrutiny following several significant developments, including a reverse stock split and a merger with Decoy Therapeutics. The halt in trading is a common practice when companies have important news to disclose, allowing investors to digest the information before resuming trading.In the recent past, Salarius Pharmaceuticals has been actively working on its reverse stock split, which was announced on August 14, 2025. The company aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement by reducing its outstanding shares from approximately 7.6 million to 509,000 shares. This move is expected to take effect on August 18, 2025 [1].
Additionally, Salarius Pharmaceuticals has been making significant strides in its oncology drug development. The company has reported promising clinical trial results for its LSD1 inhibitor seclidemstat (SP-2577), which is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [2]. The drug has shown supporting evidence in inhibiting LSD1, a validated target in cancer treatment.
Furthermore, Salarius Pharmaceuticals has announced a merger with Decoy Therapeutics, a private preclinical biopharmaceutical company. The merger, announced on January 13, 2025, aims to form a new entity focused on developing peptide conjugate therapeutics for respiratory viruses and cancer. The combined company will leverage Decoy's IMP3ACT™ platform for rapid drug design [3].
The pending news is likely related to these ongoing developments or other significant announcements that Salarius Pharmaceuticals may have in store. Investors are advised to monitor the situation closely and stay updated on any official communications from the company.
References:
[1] https://www.stocktitan.net/news/SLRX/
[2] https://www.stocktitan.net/news/SLRX/
[3] https://www.stocktitan.net/news/SLRX/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet